Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06859294 | A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis | PHASE2 | ACTIVE NOT_RECRUITING | 35 | — | — | Mar 19, 2025 | May 1, 2026 | Apr 21, 2026 | 20 | United States |
DAS28-hsCRP measures disease activity in 28 joints using a composite numeric score. Total scores range from 1.0 to 9.4, where a lower score indicates less disease activity.
| Arm | Type | Description |
|---|---|---|
| LY3541860 | EXPERIMENTAL | LY3541860 will be administered intravenously (IV). |
| Name | Type | Description |
|---|---|---|
| LY3541860 | DRUG | Administered IV |
Inclusion Criteria: * Have a diagnosis of adult-onset Rheumatoid Arthritis (RA) for at least 3 months prior to screening, as defined by the 2010 ACR/EULAR classification criteria. * Have moderately to severely active RA, at screening (Visit 1) and baseline (Visit 2), defined by the presence of *...